The surveillance study of nausea and vomiting associated with transcatheter arterial chemoembolization for hepatocellular carcinoma
Not Applicable
- Conditions
- Hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000005839
- Lead Sponsor
- Osaka University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
Not provided
Exclusion Criteria
(1)Child Pugh score C (2)hepatic encephalopathy II or more (3)total bilirubin 3.0mg/dL or more (4)the patients who are treated for neuropsychiatric disorder (5)the patients who takes anti-anxiety agent (6)the patients who takes Pimozide (7)the patients who are judged to be ineligible for entry of this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcomes of this study is the incidence of nausea and vomiting without antiemetic drugs and the rate of symptom amelioration by antiemetic drugs after transcatheter arterial chemoembolization for hepatocellular carcinoma.
- Secondary Outcome Measures
Name Time Method